3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
Oxaliplatin
10
pembrolizumab
8
Fluorouracil
8
Leucovorin
7
Paclitaxel
5
Gemcitabine
5
Docetaxel
5
Capecitabine
5
Cyclophosphamide
4
Blood Specimen Collection
4
zolbetuximab
3
fludarabine
3
darolutamide
3
cemiplimab
3
Trastuzumab
3
Taxes
3
Ramucirumab
3
Radiotherapy
3
Radiosurgery
3
Irinotecan
3
trastuzumab deruxtecan
2
enzalutamide
2
durvalumab
2
Standard of Care
2
Nivolumab
2
Folfox protocol
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled
NCT04379596
2026-05-13
DG-03
AstraZeneca
Phase 2
Recruiting
450 enrolled